Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 NPY receptors as potential targets for anti-obesity drug development.

Literature DB >> 21545413

NPY receptors as potential targets for anti-obesity drug development.

Ernie Yulyaningsih¹, Lei Zhang, Herbert Herzog, Amanda Sainsbury.

Abstract

The neuropeptide Y system has proven to be one of the most important regulators of feeding behaviour and energy homeostasis, thus presenting great potential as a therapeutic target for the treatment of disorders such as obesity and at the other extreme, anorexia. Due to the initial lack of pharmacological tools that are active in vivo, functions of the different Y receptors have been mainly studied in knockout and transgenic mouse models. However, over recent years various Y receptor selective peptidic and non-peptidic agonists and antagonists have been developed and tested. Their therapeutic potential in relation to treating obesity and other disorders of energy homeostasis is discussed in this review.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21545413 PMCID： PMC3144533 DOI： 10.1111/j.1476-5381.2011.01363.x

Source DB: PubMed Journal: Br J Pharmacol ISSN： 0007-1188 Impact factor: 8.739

244 in total

1. Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats.

Authors: Prasanth K Chelikani; Alvin C Haver; Joseph R Reeve; David A Keire; Roger D Reidelberger
Journal: Am J Physiol Regul Integr Comp Physiol Date: 2005-10-06 Impact factor: 3.619

Review 2. Chemokines and chemokine receptors in the brain: implication in neuroendocrine regulation.

Authors: Céline Callewaere; Ghazal Banisadr; William Rostène; Stéphane Mélik Parsadaniantz
Journal: J Mol Endocrinol Date: 2007-03 Impact factor: 5.098

3. Whole-body insulin resistance in the absence of obesity in FVB mice with overexpression of Dgat1 in adipose tissue.

Authors: Nancy Chen; Li Liu; Yiying Zhang; Henry N Ginsberg; Yi-Hao Yu
Journal: Diabetes Date: 2005-12 Impact factor: 9.461

4. PYY and NPY: control of gastric motility via action on Y1 and Y2 receptors in the DVC.

Authors: C H Chen; R L Stephens; R C Rogers
Journal: Neurogastroenterol Motil Date: 1997-06 Impact factor: 3.598

5. Y4 receptors and pancreatic polypeptide regulate food intake via hypothalamic orexin and brain-derived neurotropic factor dependent pathways.

Authors: Amanda Sainsbury; Yan-Chuan Shi; Lei Zhang; Aygul Aljanova; Zhou Lin; Amy D Nguyen; Herbert Herzog; Shu Lin
Journal: Neuropeptides Date: 2010-02-08 Impact factor: 3.286

6. Structure-activity studies including a Psi(CH(2)-NH) scan of peptide YY (PYY) active site, PYY(22-36), for interaction with rat intestinal PYY receptors: development of analogues with potent in vivo activity in the intestine.

Authors: A Balasubramaniam; Z Tao; W Zhai; M Stein; S Sheriff; W T Chance; J E Fischer; P E Eden; J E Taylor; C D Liu; D W McFadden; T Voisin; C Roze; M Laburthe
Journal: J Med Chem Date: 2000-09-07 Impact factor: 7.446

7. Evidence for different pre-and post-junctional receptors for neuropeptide Y and related peptides.

Authors: C Wahlestedt; N Yanaihara; R Håkanson
Journal: Regul Pept Date: 1986-02

8. Centrally truncated and stabilized porcine neuropeptide Y analogs: design, synthesis, and mouse brain receptor binding.

Authors: J L Krstenansky; T J Owen; S H Buck; K A Hagaman; L R McLean
Journal: Proc Natl Acad Sci U S A Date: 1989-06 Impact factor: 11.205

9. Expression of the human neuropeptide tyrosine Y1 receptor.

Authors: J Wharton; L Gordon; J Byrne; H Herzog; L A Selbie; K Moore; M H Sullivan; M G Elder; G Moscoso; K M Taylor
Journal: Proc Natl Acad Sci U S A Date: 1993-01-15 Impact factor: 11.205

10. Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a small molecule antagonist of the neuropeptide Y Y2 receptor.

Authors: Pascal Bonaventure; Diane Nepomuceno; Curt Mazur; Brian Lord; Dale A Rudolph; Jill A Jablonowski; Nicholas I Carruthers; Timothy W Lovenberg
Journal: J Pharmacol Exp Ther Date: 2003-11-14 Impact factor: 4.030

41 in total

1. Position and length of fatty acids strongly affect receptor selectivity pattern of human pancreatic polypeptide analogues.

Authors: Veronika Mäde; Kathrin Bellmann-Sickert; Anette Kaiser; Jens Meiler; Annette G Beck-Sickinger
Journal: ChemMedChem Date: 2014-08-22 Impact factor: 3.466

Review 2. NPY and stress 30 years later: the peripheral view.

Authors: Dalay Hirsch; Zofia Zukowska
Journal: Cell Mol Neurobiol Date: 2012-01-24 Impact factor: 5.046

3. Optogenetic activation of short neuropeptide F (sNPF) neurons induces sleep in Drosophila melanogaster.

Authors: Benjamin A Juneau; Jamie M Stonemetz; Ryan F Toma; Debra R Possidente; R Conor Heins; Christopher G Vecsey
Journal: Physiol Behav Date: 2019-03-29

4. Peptide modifications differentially alter G protein-coupled receptor internalization and signaling bias.

Authors: Veronika Mäde; Stefanie Babilon; Navjeet Jolly; Lizzy Wanka; Kathrin Bellmann-Sickert; Luis E Diaz Gimenez; Karin Mörl; Helen M Cox; Vsevolod V Gurevich; Annette G Beck-Sickinger
Journal: Angew Chem Int Ed Engl Date: 2014-07-25 Impact factor: 15.336